Special Issue

Personalized Diagnosis and Treatment of Pulmonary Diseases

Message from the Guest Editor

"Personalized medicine" has achieved great progress in the diagnosis and treatment of pulmonary diseases. However, due to the heterogeneous presentation, treatment response, and prognosis of many pulmonary diseases, we are still facing unmet requirements to give a better outcome beyond "today's personalized medicine". We need more studies connecting phenotypes to endotypes, which can help to identify potential biomarkers and treatable traits in various pulmonary diseases. This Special Issue of the *JPM* aims to provide the latest studies in the personalized diagnosis and treatment of pulmonary diseases, especially in the field of airway diseases (asthma, bronchiectasis, and chronic obstructive pulmonary disease (COPD)), cough, mycobacterial pulmonary diseases, lung cancer, and other lung diseases. We welcome clinical or translational studies evaluating phenotypes or endotypes of pulmonary diseases using advanced techniques (e.g., omics technologies (genomics and epigenomics, transcriptomics, proteomics, metabolomics, microbiomics, imaging, and functional analyses), health big data analyses, observational studies, etc.).

Guest Editor

Prof. Dr. Hyun Lee
Division of Pulmonary Medicine and Allergy, Department of Internal Medicine, Hanyang University College of Medicine, Seoul 04763, Korea

Deadline for manuscript submissions

closed (28 February 2023)

Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed

mdpi.com/si/105526

Journal of Personalized Medicine
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/jpm

Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed

mdpi.com/journal/jpm

MDPI

About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on "omics"-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical
subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker
Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 25 days after submission; acceptance to publication is undertaken in 5.8 days (median values for papers published in this journal in the second half of 2025).